{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:22:12Z","timestamp":1778628132403,"version":"3.51.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,4,10]],"date-time":"2009-04-10T00:00:00Z","timestamp":1239321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00115-009-2701-9","type":"journal-article","created":{"date-parts":[[2009,4,8]],"date-time":"2009-04-08T15:07:45Z","timestamp":1239203265000},"page":"1143-1153","source":"Crossref","is-referenced-by-count":4,"title":["Progressive multifokale Leukenzephalopathie","Progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"80","author":[{"given":"H.-P.","family":"Hartung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,10]]},"reference":[{"key":"2701_CR1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/1352458506073116","volume":"13","author":"Alvarez-Lafuente","year":"2007","unstructured":"Alvarez-Lafuente R, Garc\u00eda-Montojo M, De Las Heras V et al (2007) JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Mult Scler 13:590\u2013595","journal-title":"Mult Scler"},{"key":"2701_CR2","first-page":"27","volume":"15","author":"Baldinetti","year":"2008","unstructured":"Baldinetti F, Belcher G, Bozic C (2008) Natalizumab utilization and safety: latest results from TOUCH and TYGRIS. Eur J Neurol 15:27\u201328","journal-title":"Eur J Neurol"},{"key":"2701_CR3","doi-asserted-by":"crossref","unstructured":"Berger JR (2006) Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65 [Suppl 3]:48\u201353","DOI":"10.1136\/ard.2006.058404"},{"key":"2701_CR4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285","journal-title":"JAMA"},{"key":"2701_CR5","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2007-09-112052","volume":"111","author":"Bonig","year":"2008","unstructured":"Bonig H, Wundes A, Chang K et al (2008) Increased numbers of circulating hematopoietic stem\/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111:3439\u20133441","journal-title":"Blood"},{"key":"2701_CR6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"Boren","year":"2008","unstructured":"Boren EJ, Cheema GS, Naguwa SM et al (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30:90\u201398","journal-title":"J Autoimmun"},{"key":"2701_CR7","first-page":"68","volume":"13","author":"Brickelmaier","year":"2007","unstructured":"Brickelmaier M, Lugovskoy A, Simon K (2007) Identification and characterisation of mefloquine efficacy against JC virus in vitro. J Neurovirol 13:68 (Abstract)","journal-title":"J Neurovirol"},{"key":"2701_CR8","first-page":"44","volume":"14","author":"Brickelmaier","year":"2008","unstructured":"Brickelmaier M, Allaire N, Gorelik L (2008) Searching for novel therapeutics with anti-JCV activity among known bioactive drugs and experimental compounds. Mult Scler 14:44 (Abstract)","journal-title":"Mult Scler"},{"key":"2701_CR9","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"Calabrese","year":"2007","unstructured":"Calabrese LH, Molloy ES, Huang D et al (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56:2116\u20132128","journal-title":"Arthritis Rheum"},{"key":"2701_CR10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/NEN.0b013e318180e631","volume":"67","author":"Del","year":"2008","unstructured":"Del Valle L, White MK, Khalili K (2008) Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol 67:729\u2013740","journal-title":"J Neuropathol Exp Neurol"},{"key":"2701_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13550280601094563","volume":"13","author":"Delbue","year":"2007","unstructured":"Delbue S, Guerini FR, Mancuso R et al (2007) JC virus viremia in interferon-beta-treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 13:73\u201377","journal-title":"J Neurovirol"},{"key":"2701_CR12","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","volume":"127","author":"Du","year":"2004","unstructured":"Du Pasquier RA, Kuroda MJ, Zheng Y et al (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127:1970\u20131978","journal-title":"Brain"},{"key":"2701_CR13","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1128\/JCM.00844-08","volume":"46","author":"Dumonceaux","year":"2008","unstructured":"Dumonceaux TJ, Mesa C, Severini A (2008) Internally controlled triplex quantitative PCR assay for human polyomaviruses JC and BK. J Clin Microbiol 46:2829\u20132836","journal-title":"J Clin Microbiol"},{"key":"2701_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"Falc\u00f3","year":"2008","unstructured":"Falc\u00f3 V, Olmo M, del Saz SV et al (2008) Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49:26\u201331","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2701_CR15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jmv.20697","volume":"78","author":"Fedele","year":"2006","unstructured":"Fedele CG, Polo C, Tenorio A et al (2006) Analysis of the transcriptional control region of JC polyomavirus in cerebrospinal fluid from HIV-negative patients with progressive multifocal leucoencephalopathy. J Med Virol 78:1271\u20131275","journal-title":"J Med Virol"},{"key":"2701_CR16","unstructured":"Fox R, Man S, Tucky B (2009) Plasma exchange augments leukocyte transmigration across an in vitro blood-brain barrier in Natalizumab-treated patients with multiple sclerosis. Neurology in press"},{"key":"2701_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.20492","volume":"80","author":"Garc\u00eda-Su\u00e1rez","year":"2005","unstructured":"Garc\u00eda-Su\u00e1rez J, de Miguel D, Krsnik I et al (2005) Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80:271\u2013281","journal-title":"Am J Hematol"},{"key":"2701_CR18","unstructured":"Gold R (2009) Ruhr-Universit\u00e4t Bochum. Pers\u00f6nliche Mitteilung"},{"key":"2701_CR19","unstructured":"Gold R, Wenning W, Haghikia A (2008) Treatment of PML unfolding during monotherapy with Natalizumab. ECTRIMS, Montreal"},{"key":"2701_CR20","doi-asserted-by":"crossref","unstructured":"Hartman EA, Huang D (2008) Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment. Curr HIV\/AIDS Rep 5:112\u2013119","DOI":"10.1007\/s11904-008-0018-0"},{"key":"2701_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.wco.0000227037.70329.b0","volume":"19","author":"Hemmer","year":"2006","unstructured":"Hemmer B, Frohman E, Hartung HP et al (2006) Central nervous system infections \u2013 a potential complication of systemic immunotherapy. Curr Opin Neurol 19:271\u2013276","journal-title":"Curr Opin Neurol"},{"key":"2701_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","volume":"318","author":"Houff","year":"1988","unstructured":"Houff SA, Major EO, Katz DA et al (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318:301\u2013305","journal-title":"N Engl J Med"},{"key":"2701_CR23","first-page":"160","volume":"199","author":"Houff","year":"2008","unstructured":"Houff SA, Berger J, Major EO (2008) Response to Linberg et al Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 199:160\u2013161","journal-title":"J Neuroimmunol"},{"key":"2701_CR24","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00746941?term=mefloquine+and+pml&rank=1. Zugriff am 10.01.2009"},{"key":"2701_CR25","unstructured":"http:\/\/www.biogenidec.com\/site\/tysabri-information-center.html. Zugriff am 10.01.2009"},{"key":"2701_CR26","unstructured":"http:\/\/www.fda.gov\/cder\/drug\/infopage\/natalizumab\/. Zugriff am 10.01.2009"},{"key":"2701_CR27","unstructured":"http:\/\/www.fda.gov\/medwatch\/safety\/2008\/safety08.htm#Raptiva. Zugriff am 10.01.2009"},{"key":"2701_CR28","doi-asserted-by":"crossref","unstructured":"Iacobaeus E, Ryschkewitsch C, Gravell M et al (2008) Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18805840 [Accessed December 15, 2008]","DOI":"10.1177\/1352458508096870"},{"key":"2701_CR29","unstructured":"Imperiale M, Major EO (2007) Polyomaviruses. Fields Virology, 5th ed, pp\u00a02263\u20132298"},{"key":"2701_CR30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung H et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013441","journal-title":"Lancet Neurol"},{"key":"2701_CR31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1191\/135248506ms1264oa","volume":"12","author":"Khalili","year":"2006","unstructured":"Khalili K, White MK (2006) Human demyelinating disease and the polyomavirus JCV. Mult Scler 12:133\u2013142","journal-title":"Mult Scler"},{"key":"2701_CR32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1212\/01.wnl.0000257832.38943.2b","volume":"68","author":"Khalili","year":"2007","unstructured":"Khalili K, White MK, Lublin F et al (2007) Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68:985\u2013990","journal-title":"Neurology"},{"key":"2701_CR33","doi-asserted-by":"crossref","unstructured":"Khatri B, Fox R, Koo A (2009) The effect of plasma exchange in accelerating clearance of natalizumab in patients with mulitple sclerosis: results of the PLEX study. Neurology (in press)","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"2701_CR34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"2701_CR35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jmv.21153","volume":"80","author":"Kmieciak","year":"2008","unstructured":"Kmieciak D, Debicki S, Trzeciak WH (2008) Occurrence rate and genotype distribution of the JC virus (JCV) in a sample from the Polish population. J Med Virol 80:1079\u20131083","journal-title":"J Med Virol"},{"key":"2701_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00019052-200406000-00019","volume":"17","author":"Koralnik","year":"2004","unstructured":"Koralnik IJ (2004) New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 17:365\u2013370","journal-title":"Curr Opin Neurol"},{"key":"2701_CR37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.20933","volume":"60","author":"Koralnik","year":"2006","unstructured":"Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 60:162\u2013173","journal-title":"Ann Neurol"},{"key":"2701_CR38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/13550289909029484","volume":"5","author":"Koralnik","year":"1999","unstructured":"Koralnik IJ, Schmitz JE, Lifton MA et al (1999) Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J Neurovirol 5:430\u2013435","journal-title":"J Neurovirol"},{"key":"2701_CR39","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJMcpc030038","volume":"350","author":"Koralnik","year":"2004","unstructured":"Koralnik IJ, Schellingerhout D, Frosch MP (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med 350:1882\u20131893","journal-title":"N Engl J Med"},{"key":"2701_CR40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.wnl.0000267325.06000.d9","volume":"69","author":"Kranick","year":"2007","unstructured":"Kranick SM, Mowry EM, Rosenfeld MR (2007) Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69:704\u2013706","journal-title":"Neurology"},{"key":"2701_CR41","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, K\u00fcmpfel T et al (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71:1350\u20131354","journal-title":"Neurology"},{"key":"2701_CR42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcv.2008.07.003","volume":"43","author":"Landry","year":"2008","unstructured":"Landry ML, Eid T, Bannykh S et al (2008) False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol 43:247\u2013249","journal-title":"J Clin Virol"},{"key":"2701_CR43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"2701_CR44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"Lin","year":"2008","unstructured":"Lin J, Ziring D, Desai S et al (2008) TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126:13\u201330","journal-title":"Clin Immunol"},{"key":"2701_CR45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","volume":"194","author":"Lindberg","year":"2008","unstructured":"Lindberg RLP, Achtnichts L, Hoffmann F et al (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194:153\u2013164","journal-title":"J Neuroimmunol"},{"key":"2701_CR46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","volume":"43","author":"Martin","year":"2006","unstructured":"Martin SI, Marty FM, Fiumara K et al (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16\u201324","journal-title":"Clin Infect Dis"},{"key":"2701_CR47","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","volume":"65","author":"Martin","year":"2008","unstructured":"Martin MDP, Cravens PD, Winger R et al (2008) Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Arch Neurol 65:1596\u20131603","journal-title":"Arch Neurol"},{"key":"2701_CR48","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1128\/JCM.43.8.4175-4177.2005","volume":"43","author":"Marzocchetti","year":"2005","unstructured":"Marzocchetti A, Di Giambenedetto S, Cingolani A et al (2005) Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43:4175\u20134177","journal-title":"J Clin Microbiol"},{"key":"2701_CR49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/13550280701381324","volume":"13","author":"Marzocchetti","year":"2007","unstructured":"Marzocchetti A, Sanguinetti M, Giambenedetto SD et al (2007) Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. J Neurovirol 13:338\u2013346","journal-title":"J Neurovirol"},{"key":"2701_CR50","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/JVI.70.10.7004-7012.1996","volume":"70","author":"Monaco","year":"1996","unstructured":"Monaco MC, Atwood WJ, Gravell M et al (1996) JC virus infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells: implications for viral latency. J Virol 70:7004\u20137012","journal-title":"J Virol"},{"key":"2701_CR51","doi-asserted-by":"crossref","first-page":"9687","DOI":"10.1128\/JVI.75.20.9687-9695.2001","volume":"75","author":"Monaco","year":"2001","unstructured":"Monaco MC, Sabath BF, Durham LC et al (2001) JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J Virol 75:9687\u20139695","journal-title":"J Virol"},{"key":"2701_CR52","unstructured":"Munschauer F, Giovannoni G, Lublin F (2008) Natalizumab significantly increases the cumulative probability of sustainded disability improvement in physical disability. Mult Scler 14 [Suppl 1]:P474 (Abstract)"},{"key":"2701_CR53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0961203308089445","volume":"17","author":"Nived","year":"2008","unstructured":"Nived O, Bengtsson AA, J\u00f6nsen A et al (2008) Progressive multifocal leukoencephalopathy \u2013 the importance of early diagnosis illustrated in four cases. Lupus 17:1036\u20131041","journal-title":"Lupus"},{"key":"2701_CR54","unstructured":"O\u2019Connor P, Goodman A, Kappos L et al (2006) Results of clinical and magnetic resonance imaging analyses following cessatin of natalizumab dosin in patients with multiple sclerosis. Mult Scler 12 [Suppl. 1]:17 (Abstract)"},{"key":"2701_CR55","unstructured":"O\u2019Connor P, Goodman A, Kappos L et al (2007) The efficacy of natalizumab over 3 years of treatment in patients with relapsing multiple sclerosis. Neurology 66 [Suppl 1]:P06.082 (Abstract)"},{"key":"2701_CR56","unstructured":"Olsson T (2009) Karolinska Institut, Stockholm. Pers\u00f6nliche Mitteilung"},{"key":"2701_CR57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00277-007-0411-6","volume":"87","author":"Pelosini","year":"2008","unstructured":"Pelosini M, Focosi D, Rita F et al (2008) Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 87:405\u2013412","journal-title":"Ann Hematol"},{"key":"2701_CR58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.21443","volume":"64","author":"Perez-Liz","year":"2008","unstructured":"Perez-Liz G, Del Valle L, Gentilella A et al (2008). Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 64:379\u2013387","journal-title":"Ann Neurol"},{"key":"2701_CR59","first-page":"1633","volume":"57","author":"Pineton","year":"2008","unstructured":"Pineton de Chambrun G, Vernier-Massouille G et al (2008) Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn\u2019s disease patients eligible for anti-alpha4 integrin therapy? Gut 57:1633\u20131634","journal-title":"Gut"},{"key":"2701_CR60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"2701_CR61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/nn1005-1275","volume":"8","author":"Ransohoff","year":"2005","unstructured":"Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275","journal-title":"Nat Neurosci"},{"key":"2701_CR62","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","volume":"356","author":"Ransohoff","year":"2007","unstructured":"Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356:2622\u20132629","journal-title":"N Engl J Med"},{"key":"2701_CR63","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"Rice","year":"2005","unstructured":"Rice GPA, Hartung H, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64:1336\u20131342","journal-title":"Neurology"},{"key":"2701_CR64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/0-387-32957-9_17","volume":"577","author":"Roskopf","year":"2006","unstructured":"Roskopf J, Trofe J, Stratta RJ et al (2006) Pharmacotherapeutic options for the management of human polyomaviruses. Adv Exp Med Biol 577:228\u2013254","journal-title":"Adv Exp Med Biol"},{"key":"2701_CR65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","volume":"62","author":"Rudick","year":"2007","unstructured":"Rudick RA, Miller D, Hass S et al (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62:335\u2013346","journal-title":"Ann Neurol"},{"key":"2701_CR66","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"2701_CR67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jviromet.2004.06.021","volume":"121","author":"Ryschkewitsch","year":"2004","unstructured":"Ryschkewitsch C, Jensen P, Hou J et al (2004) Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 121(2):217\u2013221","journal-title":"J Virol Methods"},{"key":"2701_CR68","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1177\/0961203308089435","volume":"17","author":"Shprecher","year":"2008","unstructured":"Shprecher D, Frech T, Chin S et al (2008) Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus 17:1029\u20131032","journal-title":"Lupus"},{"key":"2701_CR69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Jerome KR et al (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743\u2013747","journal-title":"Ann Neurol"},{"key":"2701_CR70","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","volume":"63","author":"St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Bar-Or A et al (2006) Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63:1383\u20131387","journal-title":"Arch Neurol"},{"key":"2701_CR71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archneur.64.2.169","volume":"64","author":"St\u00fcve","year":"2007","unstructured":"St\u00fcve O, Marra CM, Cravens PD et al (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64:169\u2013176","journal-title":"Arch Neurol"},{"key":"2701_CR72","doi-asserted-by":"crossref","unstructured":"St\u00fcve O, Cravens PD, Frohman EM et al (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology in press","DOI":"10.1212\/01.wnl.0000327341.89587.76"},{"key":"2701_CR73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ana.410310426","volume":"31","author":"Tornatore","year":"1992","unstructured":"Tornatore C, Berger JR, Houff SA et al (1992) Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 31:454\u2013462","journal-title":"Ann Neurol"},{"key":"2701_CR74","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"2701_CR75","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F et al (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150\u20131151","journal-title":"Neurology"},{"key":"2701_CR76","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1212\/01.wnl.0000227922.22293.93","volume":"67","author":"Venkataramana","year":"2006","unstructured":"Venkataramana A, Pardo CA, McArthur JC et al (2006) Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67:383\u2013388","journal-title":"Neurology"},{"key":"2701_CR77","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/gut.2007.145698","volume":"57","author":"Verbeeck","year":"2008","unstructured":"Verbeeck J, Van Assche G, Ryding J et al (2008) JC viral loads in patients with Crohn\u2019s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393\u20131397","journal-title":"Gut"},{"key":"2701_CR78","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"},{"key":"2701_CR79","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","volume":"111","author":"Zohren","year":"2008","unstructured":"Zohren F, Toutzaris D, Kl\u00e4rner V et al (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111:3893\u20133895","journal-title":"Blood"},{"key":"2701_CR80","doi-asserted-by":"crossref","unstructured":"Tan K, Roda R, Ostrow L et al (2009) PML-JRJS in patients with HIV-infection. Clinical manifestation and treatment with steroids. Neurology (in press)","DOI":"10.1212\/01.wnl.0000343510.08643.74"},{"key":"2701_CR81","doi-asserted-by":"crossref","unstructured":"Berger JR (2009) Steroids for PML-JRJS. A double-edged sword? Neurology (in press)","DOI":"10.1212\/01.wnl.0000343735.44983.5e"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-009-2701-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-009-2701-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-009-2701-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T19:56:28Z","timestamp":1684958188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-009-2701-9"}},"subtitle":["Unerw\u00fcnschte Nebenwirkung einer Immuntherapie","Undesirable side effect of immunotherapy"],"short-title":[],"issued":{"date-parts":[[2009,4,10]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1007\/s00115-009-2701-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,10]]}}}